This is the sixth special report that the European Society for Blood and Marrow
Transplantation regularly publishes on the current practice and indications for …

Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …

Survival of myeloma patients has greatly improved with the use of autologous stem cell
transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs …

Multiple myeloma is a disease typical of the elderly, and, because of the increase in life
expectancy of the general population, its incidence is expected to grow in the future. Elderly …

Answer questions and earn CME/CNE Multiple myeloma (MM) is a cancer of antibody‐
producing plasma cells. The pathognomonic laboratory finding is a monoclonal …

Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past
decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered …

An estimated 22 350 patients had multiple myeloma diagnosed in 2013, representing 1.3%
of all new cancers; 10 710 deaths are projected, representing 1.8% of cancer deaths …

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor
cells into patients with hematologic disorders with the goal of re-establishing normal …

The literature is limited regarding outcomes in older adults and frail patients receiving BCMA-
directed chimeric antigen receptor T cell therapy (CAR-T) for relapsed or refractory multiple …